{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:23:22Z","timestamp":1787318602368,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104975","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:27:41Z","timestamp":1759541261000},"page":"104975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Immune checkpoint inhibitors with trastuzumab and chemotherapy in advanced HER2-positive gastric cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"216","author":[{"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Henrique Rios","family":"Moreira Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Alves","family":"de Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Tadeu Freitas","family":"Uch\u00f4a Matheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104975_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1302811","article-title":"Methods to analyze Time-to-Event data: the cox regression analysis","volume":"2021","author":"Abd ElHafeez","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.critrevonc.2025.104975_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.critrevonc.2025.104975_bib3","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s10120-018-00909-5","article-title":"Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study","volume":"22","author":"Bang","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2025.104975_bib4","doi-asserted-by":"crossref","unstructured":"Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., R\u00fcschoff, J., Kang, Y.-K., ToGA Trial Investigators, 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"10.1016\/j.critrevonc.2025.104975_bib5","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104975_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104617","article-title":"Development of treatment strategies for advanced HER2-positive gastric cancer: insights from clinical trials","volume":"207","author":"Cai","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","article-title":"Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion","volume":"430","author":"Chaganty","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104975_bib8","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","article-title":"Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104975_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190850","article-title":"An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fon-2020-0737","article-title":"First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811","volume":"17","author":"Chung","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev. 10 ED000142"},{"key":"10.1016\/j.critrevonc.2025.104975_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12029-024-01141-4","article-title":"PD-1\/PD-L1 inhibitors increase pathological complete response in locally advanced gastric cancer: a Meta-analysis and trial sequential analysis","volume":"56","author":"de Moraes","year":"2025","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104975_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1166040","article-title":"Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study","volume":"13","author":"Deng","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib14","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","article-title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","volume":"26","author":"Elimova","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1634\/theoncologist.2018-0221","article-title":"FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1","volume":"24","author":"Fashoyin-Aje","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104975_bib16","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.3390\/cancers14153824","article-title":"HER2 inhibition in gastric Cancer-Novel therapeutic approaches for an established target","volume":"14","author":"Fong","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104975_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","article-title":"Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial","volume":"25","author":"Fuchs","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2025.104975_bib18","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1158\/0008-5472.CAN-16-2774","article-title":"Trastuzumab increases HER2 uptake and Cross-Presentation by dendritic cells","volume":"77","author":"Gall","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104975_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568931","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment","volume":"11","author":"Hudson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib20","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.critrevonc.2025.104975_bib21","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104975_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104975_bib23","article-title":"First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma","volume":"37","author":"Janjigian","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104975_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104975_bib25","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1093\/annonc\/mds104","article-title":"Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a european and USA international collaborative analysis","volume":"23","author":"Janjigian","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5230\/jgc.2024.24.e6","article-title":"Emerging targets for systemic treatment of gastric cancer: HER2 and beyond","volume":"24","author":"Kim","year":"2024","journal-title":"J. Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2025.104975_bib27","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","author":"Liang","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib28","article-title":"Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib30","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2730","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib31","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"M\u00fcller","year":"2015","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104975_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib34","article-title":"Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"6","author":"Nie","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2025.104975_bib35","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ 372"},{"key":"10.1016\/j.critrevonc.2025.104975_bib36","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1200\/JCO.21.02500","article-title":"Esophagogastric cancers: integrating immunotherapy therapy into current practice","volume":"40","author":"Patel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib37","doi-asserted-by":"crossref","first-page":"11403","DOI":"10.3390\/ijms241411403","article-title":"HER2-positive gastric cancer: the role of immunotherapy and novel therapeutic strategies","volume":"24","author":"Pous","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104975_bib38","unstructured":"Resources for Researchers: Common Terminology Criteria for Adverse Events (CTCAE) - National Cancer Institute [WWW Document], 2018. URL https:\/\/www.cancer.gov\/research\/resources (accessed 9.19.25)."},{"key":"10.1016\/j.critrevonc.2025.104975_bib39","volume":"38","author":"Rha","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104975_bib40","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib41","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104975_bib42","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104975_bib43","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with First-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10120-012-0179-9","article-title":"Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment","volume":"16","author":"Shitara","year":"2013","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.critrevonc.2025.104975_bib45","article-title":"The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019","volume":"12","author":"Song","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104975_bib46","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ 355"},{"key":"10.1016\/j.critrevonc.2025.104975_bib47","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ 366"},{"key":"10.1016\/j.critrevonc.2025.104975_bib48","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104975_bib49","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104975_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/ajcp\/aqz020","article-title":"The PD-1\/PD-L1 axis in HER2+ ductal carcinoma in situ (DCIS) of the breast","volume":"152","author":"Ubago","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib52","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib53","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1158\/1078-0432.CCR-15-2021","article-title":"Immune signatures following single dose trastuzumab predict pathologic response to preoperative trastuzumab and chemotherapy in HER2-Positive early breast cancer","volume":"22","author":"Varadan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104975_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I(2) can be biased in small meta-analyses","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.critrevonc.2025.104975_bib55","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3389\/fphar.2018.00536","article-title":"Regulation of PD-L1: emerging routes for targeting tumor immune evasion","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104975_bib56","doi-asserted-by":"crossref","first-page":"548","DOI":"10.21037\/jgo-21-897","article-title":"Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer","volume":"13","author":"Xu","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib57","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine t cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/tgh-24-95","article-title":"The effective molecular characteristics of PD-1 inhibitor combination regimen as the first-line treatment for Chinese patients with HER2-positive gastric cancer: a real-world retrospective analysis study","volume":"10","author":"Zhang","year":"2025","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.104975_bib59","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00228-024-03644-2","article-title":"Progress of PD-1\/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors","volume":"80","author":"Zhao","year":"2024","journal-title":"Eur. J. Clin. Pharm."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:09:32Z","timestamp":1767388172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"alternative-id":["S1040842825003634"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104975","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors with trastuzumab and chemotherapy in advanced HER2-positive gastric cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104975"}}